share_log

CVS Health | 8-K: Current report

CVS Health | 8-K: Current report

西维斯健康 | 8-K:重大事件
美股SEC公告 ·  05/08 16:45
Moomoo AI 已提取核心信息
On May 7, 2024, CVS Health Corporation entered into an Underwriting Agreement with a consortium of underwriters led by BofA Securities, Inc., Barclays Capital Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Wells Fargo Securities, LLC. The agreement outlines the sale of $5 billion in Senior Notes with varying maturity dates ranging from 2029 to 2054 and interest rates from 5.400% to 6.050%. The sale is set to close on May 9, 2024, contingent on customary closing conditions. The net proceeds from the sale, after underwriting discounts and estimated offering expenses, are expected to be approximately $4.95 billion. The offering is made under the Company's Registration Statement on Form S-3ASR, dated May 25, 2023. The Underwriting Agreement has been filed with the SEC and is incorporated into the Registration Statement.
On May 7, 2024, CVS Health Corporation entered into an Underwriting Agreement with a consortium of underwriters led by BofA Securities, Inc., Barclays Capital Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Wells Fargo Securities, LLC. The agreement outlines the sale of $5 billion in Senior Notes with varying maturity dates ranging from 2029 to 2054 and interest rates from 5.400% to 6.050%. The sale is set to close on May 9, 2024, contingent on customary closing conditions. The net proceeds from the sale, after underwriting discounts and estimated offering expenses, are expected to be approximately $4.95 billion. The offering is made under the Company's Registration Statement on Form S-3ASR, dated May 25, 2023. The Underwriting Agreement has been filed with the SEC and is incorporated into the Registration Statement.
2024年5月7日,CVS Health Corporation与由美银证券公司、巴克莱资本公司、高盛公司牵头的承销商财团签订了承保协议。有限责任公司、摩根大通证券有限责任公司和富国银行证券有限责任公司。该协议概述了出售50亿美元的优先票据,其到期日从2029年到2054年不等,利率从5.400%到6.050%不等。此次拍卖定于2024年5月9日结束,视惯例成交条件而定。扣除承保折扣和预计发行费用后,此次出售的净收益预计约为49.5亿美元。此次发行是根据公司于 2023 年 5 月 25 日在 S-3ASR 表格上发布的注册声明进行的。承保协议已向美国证券交易委员会提交并已纳入注册声明。
2024年5月7日,CVS Health Corporation与由美银证券公司、巴克莱资本公司、高盛公司牵头的承销商财团签订了承保协议。有限责任公司、摩根大通证券有限责任公司和富国银行证券有限责任公司。该协议概述了出售50亿美元的优先票据,其到期日从2029年到2054年不等,利率从5.400%到6.050%不等。此次拍卖定于2024年5月9日结束,视惯例成交条件而定。扣除承保折扣和预计发行费用后,此次出售的净收益预计约为49.5亿美元。此次发行是根据公司于 2023 年 5 月 25 日在 S-3ASR 表格上发布的注册声明进行的。承保协议已向美国证券交易委员会提交并已纳入注册声明。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息